PHARMACOGENETIC PREDICTORS OF SEVERE CHRONIC PERIPHERAL NEUROPATHY IN STAGE II-III COLON CANCER (CC) PATIENTS TREATED WITH OXALIPLATIN-BASED ADJUVANT CHEMOTHERAPY (CT). A GEMCAD STUDY

被引：0
|
作者：
Custodio, A. [1 ]
Moreno, J. [1 ]
Aparicio, J. [2 ]
Gallego Plazas, J. [3 ]
Fernandez Martos, C. [4 ]
Maurel, J. [5 ]
Ramos, D. [6 ]
Cejas, P. [1 ]
Madero, R. [7 ]
Feliu, J. [1 ]
机构：
[1] La Paz Univ Hosp, Madrid, Spain
[2] La Fe Univ Hosp, Med Oncol Dept, Valencia, Spain
[3] Elche Univ Hosp, Med Oncol Dept, Elche, Spain
[4] Fdn Inst Valenciano Oncol, Med Oncol Dept, Valencia, Spain
[5] Hosp Clin Barcelona, Barcelona, Spain
[6] La Fe Univ Hosp, Dept Pathol, Valencia, Spain
[7] La Paz Univ Hosp, Biostat Unit, Madrid, Spain
来源：
ANNALS OF ONCOLOGY | 2012年 / 23卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：181 / 181
页数：1
相关论文
共 50 条
  • [1] Pharmacogenetic predictors of severe peripheral neuropathy in colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: a GEMCAD group study
    Custodio, A.
    Moreno-Rubio, J.
    Aparicio, J.
    Gallego-Plazas, J.
    Yaya, R.
    Maurel, J.
    Higuera, O.
    Burgos, E.
    Ramos, D.
    Calatrava, A.
    Andrada, E.
    Lopez, R.
    Moreno, V.
    Madero, R.
    Cejas, P.
    Feliu, J.
    [J]. ANNALS OF ONCOLOGY, 2014, 25 (02) : 398 - 403
  • [2] Pharmacogenetic predictors of adverse events in stage II-III colon cancer (CC) patients treated with oxaliplatin and fluoropyrimidines-based adjuvant chemotherapy (CT): A GEMCAD study
    Custodio, Ana
    Moreno, Juan
    Aparicio, Jorge
    Gallego Plazas, Javier
    Fernandez-Martos, Carlos
    Yaya, Ricardo
    Calatrava, Ana M.
    Maurel, Juan
    Burgos, Emilio
    Tejerina, Eva
    Barriuso, Jorge
    Moreno, Victor
    Martinez Marin, Virginia
    De Castro, Javier
    Lamarca, Angela
    Lapunzina, Pablo
    Madero, Rosario
    Cejas, Paloma
    Feliu, Jaime
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [3] Pharmacogenetic Predictors of Outcome in Patients with Stage II and III Colon Cancer Treated with Oxaliplatin and Fluoropyrimidine-Based Adjuvant Chemotherapy
    Custodio, Ana
    Moreno-Rubio, Juan
    Aparicio, Jorge
    Gallego-Plazas, Javier
    Yaya, Ricardo
    Maurel, Joan
    Rodriguez-Salas, Nuria
    Burgos, Emilio
    Ramos, David
    Calatrava, Ana
    Andrada, Encarna
    Diaz-Lopez, Esther
    Sanchez, Antonio
    Madero, Rosario
    Cejas, Paloma
    Feliu, Jaime
    [J]. MOLECULAR CANCER THERAPEUTICS, 2014, 13 (09) : 2226 - 2237
  • [4] phase II study of oxaliplatin-based regimen in relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy: INSPIRE study
    Kotaka, M.
    Ishibashi, K.
    Satake, H.
    Tsuji, Y.
    Kataoka, M.
    Nakamura, M.
    Nagata, N.
    Sakamoto, J.
    Oba, K.
    Mishima, H.
    [J]. ANNALS OF ONCOLOGY, 2020, 31 : S101 - S101
  • [5] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
    Keiichiro Ishibashi
    Toru Aoyama
    Masahito Kotaka
    Hironaga Satake
    Yasushi Tsuji
    Masato Kataoka
    Masato Nakamura
    Naoki Nagata
    Junichi Sakamoto
    Koji Oba
    Hideyuki Mishima
    [J]. Cancer Chemotherapy and Pharmacology, 2021, 87 : 665 - 672
  • [6] Phase II study of an oxaliplatin-based regimen for relapsed colon cancer patients treated with oxaliplatin-based adjuvant chemotherapy (INSPIRE study)
    Ishibashi, Keiichiro
    Aoyama, Toru
    Kotaka, Masahito
    Satake, Hironaga
    Tsuji, Yasushi
    Kataoka, Masato
    Nakamura, Masato
    Nagata, Naoki
    Sakamoto, Junichi
    Oba, Koji
    Mishima, Hideyuki
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2021, 87 (05) : 665 - 672
  • [7] Effect of Delay in Adjuvant Oxaliplatin-Based Chemotherapy for Stage III Colon Cancer
    Peixoto, Renata D'Alpino
    Kumar, Aalok
    Speers, Caroline
    Renouf, Daniel
    Kennecke, Hagen F.
    Lim, Howard J.
    Cheung, Winson Y.
    Melosky, Barbara
    Gill, Sharlene
    [J]. CLINICAL COLORECTAL CANCER, 2015, 14 (01) : 25 - 30
  • [8] Optimal duration of oxaliplatin-based adjuvant chemotherapy in patients with different risk factors for stage II-III colon cancer: a meta-analysis
    Kuang, Ziyu
    Wang, Jiaxi
    Liu, Kexin
    Wu, Jingyuan
    Li, Jie
    [J]. INTERNATIONAL JOURNAL OF SURGERY, 2024, 110 (05) : 3030 - 3038
  • [9] Prognostic value of methylator phenotype in stage III colon cancer treated with oxaliplatin-based adjuvant chemotherapy
    Gallois, C.
    Taieb, J.
    Le Corre, D.
    Le Malicot, K.
    Tabernero, J.
    Mulot, C.
    Seitz, J-F.
    Aparicio, T.
    Folprecht, G.
    Lepage, C.
    Mini, E.
    Van Laethem, J-L.
    Emile, J. F.
    Laurent-Puig, P.
    [J]. ANNALS OF ONCOLOGY, 2017, 28
  • [10] Prognostic Value of Methylator Phenotype in Stage III Colon Cancer Treated with Oxaliplatin-based Adjuvant Chemotherapy
    Gallois, Claire
    Taieb, Julien
    Le Corre, Delphine
    Le Malicot, Karine
    Tabernero, Josep
    Mulot, Claire
    Seitz, Jean-Francois
    Aparicio, Thomas
    Folprecht, Gunnar
    Lepage, Come
    Mini, Enrico
    Van Laethem, Jean-Luc
    Emile, Jean-Francois
    Laurent-Puig, Pierre
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (19) : 4745 - 4753
12345